지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2011.1
- 수록면
- 506 - 511 (6page)
이용수
초록· 키워드
오류제보하기
Mammalian Target of Rapamycin (mTOR) is a serine/threonine kinase and that forms two multiprotein complexes known as the mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
mTOR regulates cell growth, proliferation and survival.
mTORC1 is composed of the mTOR catalytic subunit and three associated proteins: raptor, mLST8/GβL and PRAS40.
mTORC2 contains mTOR, rictor, mLST8/GβL, mSin1, and protor.
Here, we discuss mTOR as a promising anti-ischemic agent.
It is believed that mTORC2 lies down-stream of Akt and acts as a direct activator of Akt. The different functions of mTOR can be explained by the existence of two distinct mTOR complexes containing unique interacting proteins. The loss of TSC2, which is upstream of mTOR, activates S6K1, promotes cell growth and survival, activates mTOR kinase activities,inhibits mTORC1 and mTORC2 via mTOR inhibitors,and suppresses S6K1 and Akt. Although mTOR signaling pathways are often activated in human diseases, such as cancer,mTOR signaling pathways are deactivated in ischemic diseases.
From Drosophila to humans, mTOR is necessary for Ser473 phosphorylation of Akt, and the regulation of Akt-mTOR signaling pathways may have a potential role in ischemic disease. This review evaluates the potential functions of mTOR in ischemic diseases. A novel mTOR-interacting protein deregulates over-expression in ischemic disease, representing a new mechanism for controlling mTOR signaling pathways and potential therapeutic strategies for ischemic diseases. [BMB reports 2011; 44(8): 506-511]
목차
등록된 정보가 없습니다.
참고문헌 (26)
참고문헌 신청
Bhaskar, P. T / 2007 / The two TORCs and Akt / Dev. Cell 12 : 487 ~ 502
Guertin, D. A / 2006 / Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1
Guertin, D. A / 2007 / Defining the Role of mTOR in Cancer / Cancer Cell 12 : 9 ~ 22
Hanada, M / 2004 / Structure, regulation and function of PKB/AKT?a major therapeutic target / Biochim. Biophys. Acta 1697 : 3 ~ 16
Huang, B / 2005 / Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis / Acta. Pharmacol. Sin 26 : 1253 ~ 1258
Guertin, D. A / 2006 / Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1
Guertin, D. A / 2007 / Defining the Role of mTOR in Cancer / Cancer Cell 12 : 9 ~ 22
Hanada, M / 2004 / Structure, regulation and function of PKB/AKT?a major therapeutic target / Biochim. Biophys. Acta 1697 : 3 ~ 16
Huang, B / 2005 / Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis / Acta. Pharmacol. Sin 26 : 1253 ~ 1258
이 논문의 저자 정보
최근 본 자료
댓글(0)
0